Improved potency and specificity of Arg-Gly-Asp (RGD) containing peptides as fibrinogen receptor blocking drugs
- 1 November 1993
- journal article
- Published by Elsevier in Thrombosis Research
- Vol. 72 (3) , 231-245
- https://doi.org/10.1016/0049-3848(93)90190-y
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Development of a small RGD peptide fibrinogen receptor antagonist with potent antiaggregatory activity in vitroJournal of Medicinal Chemistry, 1991
- Reactivity of synthetic peptide analogs of adhesive proteins in regard to the interaction of human endothelial cells with extracellular matrixBlood, 1991
- Molecular mechanisms of platelet activation.Physiological Reviews, 1989
- Clinical Implications of Prostaglandin and Thromboxane A2FormationNew England Journal of Medicine, 1988
- Platelet Membrane Glycoprotein IIb/IIIa: Member of a Family of Arg-Gly-Asp—Specific Adhesion ReceptorsScience, 1986
- Arg-Gly-Asp: A versatile cell recognition signalCell, 1986
- Glycoprotein IIb-IIIa complex and Ca2+ influx into stimulated plateletsBlood, 1985
- Fibronectin receptor of human macrophages recognizes the sequence Arg-Gly-Asp-Ser.The Journal of Experimental Medicine, 1985
- A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa.Journal of Clinical Investigation, 1983